ADA 2021: Top Data and Other Highlights from the American Diabetes Association’s 81st Scientific Sessions – Endocrinology Network

As part of our coverage of ADA 2021, Endocrinology Network has put together a curated list of the top most-viewed and most impactful pieces of data to come from this year's conference. Our list includes 5 topics of coverage, including how the cost of diabetes management is burdening progress, SURPASS program, a trio of FIDELIO-DKD analyses, exciting news surrounding semaglutide, and a review of data from the SCORED and SOLOIST trials.

Editor's note: Clicking on slides will link back to the article in reference. In the event multiple articles are featured within a slide, links to these articles can be found below the slideshow.

See below for links to each piece of content examining prespecified analyses of FIDELIO-DKD.

See below for links to both articles examining studies from Hui Shao, MD, PhD, focusing on the rising costs of diabetes management.

Finerenone data:

Background Insulin Use Does Not Impact Benefits of Finerenone in Diabetic Kidney Disease

Finerenone Provides Consistent Benefit, Irrespective of Background GLP-1 RA Use

Finerenone and SGLT2 Inhibitors Could Have Additive Effect on Kidney Protection

Cost of Diabetes:

Diminishing Cost-Effectiveness Hurting Case for New Glucose-Lowering Agents

Estimating the Impact of the Medicare Part D Senior Savings Model on Expenses for Insulin Users on Medicare

Read the original here:
ADA 2021: Top Data and Other Highlights from the American Diabetes Association's 81st Scientific Sessions - Endocrinology Network